Type 2 Diabetes Mellitus (T2DM) Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly
injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus (T2DM) on metformin
monotherapy. This study will be a randomized, double-blind comparison of CJC-1134-PC versus
placebo. Patients taking metformin will continue to take their metformin at the same dose
for the duration of the study.
Patients with T2DM, who meet all the inclusion criteria and none of the exclusion criteria,
will be randomly assigned to a treatment arm. All patients will undergo weekly clinic visits
to receive 17 weeks of study treatment, including the titration period.
CJC-1134-PC or placebo treatment will be administered weekly by subcutaneous injection in
the abdomen to patients in a fasting state. Patients will be closely monitored and evaluated
for toxicity on an ongoing basis.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05102149 -
Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus
|
Phase 3 | |
Withdrawn |
NCT03423355 -
Dapagliflozin Effect on Erythropoiesis and Physical Fitness
|
Phase 4 | |
Terminated |
NCT01923389 -
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
|
Phase 1 | |
Completed |
NCT02218099 -
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT05607160 -
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
|
||
Completed |
NCT05628090 -
A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India
|
||
Completed |
NCT03656744 -
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
|
Phase 2 | |
Completed |
NCT01002807 -
Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
|
Phase 1 | |
Recruiting |
NCT04943861 -
Human Immunodeficiency Virus (HIV) Food Insecurities
|
N/A | |
Completed |
NCT02759107 -
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
|
Phase 1 | |
Completed |
NCT02643797 -
Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings
|
Phase 3 | |
Completed |
NCT05294458 -
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06327815 -
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
|
Phase 4 | |
Completed |
NCT02219646 -
Diabetes & Vardenafil
|
Phase 2 | |
Recruiting |
NCT05761301 -
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
|
Phase 1/Phase 2 | |
Completed |
NCT04504396 -
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
|
Phase 3 | |
Completed |
NCT01991093 -
Multiple Electrode Aggregometry & Clopidogrel Resistance
|
||
Completed |
NCT01871558 -
Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin
|
Phase 3 | |
Completed |
NCT01407003 -
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1/Phase 2 | |
Completed |
NCT01127308 -
A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)
|
Phase 1 |